✦ LIBER ✦

Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

✍ Scribed by Arnold, A. M.; Seymour, L.; Smylie, M.; Ding, K.; Ung, Y.; Findlay, B.; Lee, C. W.; Djurfeldt, M.; Whitehead, M.; Ellis, P.; Goss, G.; Chan, A.; Meharchand, J.; Alam, Y.; Gregg, R.; Butts, C.; Langmuir, P.; Shepherd, F.

Book ID: 125518990
Publisher: American Society of Clinical Oncology
Year: 2007
Tongue: English
Weight: 134 KB
Volume: 25
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2007.12.3083

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomised phase II study of BMS-275291

Randomised phase II study of BMS-275291 versus placebo in patients (pts) with stage IIIb or IV non small cell lung cancer (NSCLC) receiving paclitaxel + carboplatin (PC): National Cancer Institute of Canada clinical trials group (NCIC CTG) br.18

✍ J. Douillard; V. Petersen; F. Shepherd; L. Paz-Ares; A. Arnold; M. Tonato; J. Ot 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 365 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB